0.00Open0.00Pre Close0 Volume0 Open Interest25.00Strike Price0.00Turnover0.00%IV-523.44%PremiumOct 18, 2024Expiry Date20.99Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.19Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Macrogenics Stock Discussion
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine(vobra duo) for metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024.
Key findings include:
▪️6-month radiographic progression-free survival (rPFS) rate: 69% for 2.0 mg...
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) announced a poster presentation of Phase 2 data for vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024. The TAMARACK trial results will be presented on September 15, 2024, featuring updated safety and efficacy data, including the primary endpoint of 6-month radiographic progression-free survival (rPFS).
Th...
f@#$%^&* up
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration With Incyte
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
No comment yet